MiR-1247-5p is overexpressed in castration resistant prostate cancer and targets MYCBP2

Prostate

Volumn 75, Issue 8, 2015, Pages 798-805

  Scaravilli, Mauro ^a   Porkka, Kati P ^a   Brofeldt, Anniina ^a   Annala, Matti ^a   Tammela, Teuvo L J ^b   Jenster, Guido W ^c   Nykter, Matti ^a   Visakorpi, Tapio ^a  

^a FIMLAB LABORATORIES   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

Author keywords

castration resistant prostate cancer; microRNA; MYCBP2

Indexed keywords

ANDROGEN; BINDING PROTEIN; MICRORNA; MICRORNA 1247 5P; MYC BINDING PROTEIN 2; UNCLASSIFIED DRUG; MESSENGER RNA; MYCBP2 PROTEIN, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; UBIQUITIN PROTEIN LIGASE;

ADULT; AGED; ARTICLE; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; PROTEIN TARGETING; UPREGULATION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED; PATHOLOGY; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AGED; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; MIDDLE AGED; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RNA, MESSENGER; UBIQUITIN-PROTEIN LIGASES;

EID: 84927794448     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22961     Document Type: Article

References (39)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D,. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-902.
2. Scher HI, Sawyers CL,. Biology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005; 23: 8253-8261.
3. Seruga B, Ocana A, Tannock IF,. Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol 2011; 8 (1): 12-23.
4. Hotte SJ, Saad F,. Current management of castrate-resistant prostate cancer. Curr Oncol 2010; 17 (Suppl. 2): S72-S79.
5. Bartel DP,. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
6. Eulalio A, Huntzinger E, Izaurralde E,. Getting to the root of miRNA-mediated gene silencing. Cell 2008; 132: 9-14.
7. Baek D, Villén J, Shin C, Camargo FD, Gygi SP, Bartel DP,. The impact of microRNAs on protein output. Nature 2008; 455: 64-71.
8. Pillai RS, Artus CG, Filipowicz W,. Tethering of human Ago proteins to mRNA mimics the miRNA-mediated repression of protein synthesis. RNA 2004; 10: 1518-1525.
9. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, Bartel DP, Linsley PS, Johnson JM,. Microarray analysis shows that some microRNAs down-regulate large numbers of target mRNAs. Nature 2005; 433: 769-773.
10. Lewis BP, Burge CB, Bartel DP,. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120: 15-20.
11. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM,. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103: 2257-2261.
12. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T,. MicroRNA expression profiling in prostate cancer. Cancer Res 2007; 67: 6130-6135.
13. Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F, Wallace TA, Liu CG, Volinia S, Calin GA, Yfantis HG, Stephens RM, Croce CM,. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res 2008; 68: 6162-6170.
14. Martens-Uzunova ES, Jalava SE, Dits NF, van Leenders GJ, Møller S, Trapman J, Bangma CH, Litman T, Visakorpi T, Jenster G,. Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer. Oncogene 2012; 31 (8): 978-991.
15. Szczyrba J, Löprich E, Wach S, Jung V, Unteregger G, Barth S, Grobholz R, Wieland W, Stöhr R, Hartmann A, Wullich B, Grässer F,. The microRNA profile of prostate carcinoma obtained by deep sequencing. Mol Cancer Res 2010; 8: 529-538.
16. Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, Jentzmik F, Miller K, Lein M, Kristiansen G, Jung K,. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer 2010; 126: 1166-1176.
17. Fang YX, Gao WQ,. Roles of microRNAs during prostatic tumorigenesis and tumor progression. Oncogene 2014; 33 (2): 135-147.
18. Ribas J, Ni X, Haffner M, Wentzel EA, Salmasi AH, Chowdhury WH, Kudrolli TA, Yegnasubramanian S, Luo J, Rodriguez R, Mendell JT, Lupold SE,. MiR-21: An androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res 2009; 69: 7165-7169.
19. Jalava SE, Urbanucci A, Latonen L, Waltering KK, Sahu B, Jänne OA, Seppälä J, Lähdesmäki H, Tammela TL, Visakorpi T,. Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer. Oncogene 2012; 31: 4460-4471.
20. Shi XB, Xue L, Ma AH, Tepper CG, Kung HJ, White RW,. MiR-125b promotes growth of prostate cancer xenograft tumor through targeting pro-apoptotic genes. Prostate 2011; 71: 538-549.
21. Porkka KP, Ogg EL, Saramäki OR, Vessella RL, Pukkila H, Lähdesmäki H, van Weerden WM, Wolf M, Kallioniemi OP, Jenster G, Visakorpi T,. The miR-15a-miR-16-1 locus is homozygously deleted in a subset of prostate cancers. Genes Chromosomes Cancer 2011; 50 (7): 499-509.
22. Rauhala HE, Jalava SE, Isotalo J, Bracken H, Lehmusvaara S, Tammela TL, Oja H, Visakorpi T,. MiR-193b is an epigenetically regulated putative tumor suppressor in prostate cancer. Int J Cancer 2010; 127 (6): 1363-1372.
23. Zhang B, Pan X, Cobb GP, Anderson TA,. MicroRNAs as oncogene and tumor suppressors. Dev Biol 2007; 302: 1-12.
24. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M,. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008; 105: 10513-10518.
25. Yun SJ, Jeong P, Kim WT, Kim TH, Lee YS, Song PH, Choi YH, Kim IY, Moon SK, Kim WJ,. Cell-free microRNAs in urine as diagnostic and prognostic biomarkers of bladder cancer. Int J Oncol 2012; 41: 1871-1878.
26. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, Li Q, Li X, Wang W, Zhang Y, Wang J, Jiang X, Xiang Y, Xu C, Zheng P, Zhang J, Li R, Zhang H, Shang X, Gong T, Ning G, Wang J, Zen K, Zhang J, Zhang CY,. Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18: 997-1006.
27. O'Kelly F, Marignol L, Meunier A, Lynch TH, Perry AS, Hollywood D,. MicroRNAs as putative mediators of treatment response in prostate cancer. Nat Rev Urol 2012; 9 (7): 397-407.
28. Gee HE, Buffa FM, Camps C, Ramachandran A, Leek R, Taylor M, Patil M, Sheldon H, Betts G, Homer J, West C, Ragoussis J, Harris AL,. The small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis. British Journal of Cancer 2011; 104 (7): 1168-1177.
29. Martinez-Sanchez A, Murphy CL,. MiR-1247-5p functions by targeting cartilage transcription factor SOX9. J Biol Chem 2013; 288 (43): 30802-30814.
30. Wang G, Lunardi A, Zhang J, Chen Z, Ala U, Webster KA, Tay Y, Gonzalez-Billalabeitia E, Egia A, Shaffer DR, Carver B, Liu XS, Taulli R, Kuo WP, Nardella C, Signoretti S, Cordon-Cardo C, Gerald WL, Pandolfi PP,. Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion. Nat Genet 2013; 45 (7): 739-746.
31. van Leenders GJ, Sookhlall R, Teubel WJ, de Ridder CM, Reneman S, Sacchetti A, Vissers KJ, van Weerden W, Jenster G,. Activation of c-MET induces a stem-like phenotype in human prostate cancer. Plos One 2011; 6 (11): e26753.
32. Shi S, Lu Y, Qin Y, Li W, Cheng H, Xu Y, Xu J, Long J, Liu L, Liu C, Yu X,. MiR-1247-5p is correlated with prognosis of pancreatic cancer and inhibits cell proliferation by targeting neuropilins. Curr Mol Med 2014; 14 (3): 316-327.
33. Guo Q, Xie J, Dang CV, Liu ET, Bishop JM,. Identification of a large Myc-binding protein that contains RCC1-like repeats. Proc Natl Acad Sci USA 1998; 95 (16): 9172-9177.
34. Yang H, Scholich K, Poser S, Storm DR, Patel TB, Goldowitz D,. Developmental expression of PAM (protein associated with MYC) in the rodent brain. Brain Res Dev Brain Res 2002; 136: 35-42.
35. Scholich K, Pierre SC, Patel TB,. Protein associated with Myc (PAM) is a potent inhibitor of adenylyl cyclases. J Biol Chem 2001; 276: 47583-47589.
36. McCabe BD, Hom S, Aberle H, Fetter RD, Marques G, Haerry TE, Wan H, O'Connor MB, Goodman CS, Haghighi AP,. Highwire regulates presynaptic BMP signaling essential for synaptic growth. Neuron 2004; 41: 891-905.
37. Han SWR, Santos TM, Polizzano C, Sabatini BL, Ramesh V,. Pam (Protein associated with Myc) functions as an E3 Ubiquitin ligase and regulates TSC/mTOR signaling. Cell Signal 2008; 20: 1084-1091.
38. Nakata KAB, Grill B, Goncharov A, Huang X, Chisholm AD, Jin Y,. Regulation of a DLK-1 and p38 MAP kinase pathway by the ubiquitin ligase RPM-1 is required for presynaptic development. Cell 2005; 120: 407-420.
39. Ayala GE, Dai H, Powell M, Li R, Ding Y, Wheeler TM, Shine D, Kadmon D, Thompson T, Miles BJ, Ittmann MM, Rowley D,. Cancer-related axonogenesis and neurogenesis in prostate cancer. Clin Cancer Res 2008; 14 (23): 7593-7603.